Ixazomib - a selective and reversible inhibitor of the protein proteasome subunit beta type-5 (PSMB5) similar to bortezomib. It contains leucine derivative with the carboxylate acid replaced by a boronic acid. It is used for the treatment of multiple myeloma together with daratumumab and elotuzumab.









